The World Health Organization currently estimates the global burden of Hepatitis C to be between 130 and 170 million people. Ideally, this figure, as well as stratifications by location, age, and ...

(HealthDay News) — Worldwide, genotype 1 is the most prevalent variant of hepatitis C virus (HCV) infections and accounts for almost half of cases, according to research published online July 28 in ...

Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...

Viekira Pak is indicated for chronic hepatitis C virus (HCV) genotype 1 infection. Viekira Pak is indicated for chronic hepatitis C virus (HCV) genotype 1 infection, with or without ribavirin. Product ...

Individuals with chronic, untreated hepatitis C virus infection may be at greater risk for pancreatic ductal adenocarcinoma, ...

If you’ve recently received a hepatitis C diagnosis, it’s understandable to feel frightened or alone. But you’re far from alone. About 2.4 million people in the United States live with chronic ...

GENT, Belgium--(BUSINESS WIRE)--Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc.

Epclusa (sofosbuvir/velpatasvir) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat hepatitis C, which is an ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...